Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rabivax-S PrEP Intradermal Regimen Comparison
NCT06066294Phase 3Completed
- Start
- Apr 2023
- Primary completion
- Mar 2024
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rabies virus inactivated antigen, A in rabies (2 arms). Primary endpoints: Seroconversion (>0.5 IU/mL) Rate at Day 375 and Incidence of Adverse Events. Started Apr 2023; status: completed.
02
Drugs
rabies virus inactivated antigen, A
03
Conditions
rabies
Beyond the preview
Go deeper on NCT06066294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06066294.